Analyst Ratings January 28, 2026

Bernstein Sticks With Outperform on Boeing After Strong Q4 Showing

Analyst keeps $298 price target as investors await company cash-flow guidance amid mixed valuation signals

By Marcus Reed BA
Bernstein Sticks With Outperform on Boeing After Strong Q4 Showing
BA

Bernstein SocGen Group maintained an Outperform rating and a $298.00 price target on Boeing following the company’s fourth-quarter results. The target implies about 22% upside from the prevailing share price of $244.56, though InvestingPro’s Fair Value model flags the stock as potentially overvalued. The quarter featured materially stronger-than-expected earnings and revenue, an improved free cash flow print, and a series of one-time items that shaped the headline results.

Key Points

  • Bernstein SocGen Group reiterated an Outperform rating and a $298.00 price target on Boeing, implying about 22% upside from $244.56.
  • Boeing’s Q4 core EPS was $9.92, significantly above consensus (-$0.49) and Bernstein’s estimate (-$0.31); quarterly revenue was $23.9 billion versus a $22.3 billion consensus.
  • Quarterly free cash flow beat estimates at $375 million, but Boeing’s levered free cash flow is still negative at -$6.35 billion over the last twelve months; several analysts adjusted price targets after the results.

Bernstein SocGen Group has reiterated an Outperform rating on Boeing (NYSE:BA) and held its $298.00 price target after the aircraft maker released fourth-quarter results. At the time cited in analyst commentary, that target represents roughly a 22% increase from Boeing’s then-current share price of $244.56. Separately, InvestingPro’s Fair Value model suggests the shares may be trading above intrinsic value according to that proprietary framework.

The company reported fourth-quarter core earnings per share of $9.92, a result that markedly outpaced both the consensus estimate of -$0.49 and Bernstein’s own estimate of -$0.31. Revenue for the quarter came in at $23.9 billion, above the consensus figure of $22.3 billion. For the full fiscal year, Boeing posted revenue of $89.46 billion, a year-over-year increase of 34.5% as reported by InvestingPro data.

Free cash flow for the quarter was reported at $375 million, exceeding the consensus expectation of $272 million. Management is expected to provide guidance on future free cash flow during its earnings call, and investor attention is likely to focus on those forward-looking metrics. Despite the quarterly improvement, Boeing’s levered free cash flow remained negative at -$6.35 billion over the last twelve months.

Bernstein analyst Douglas Harned highlighted the company’s strong revenue performance and noted progress on Boeing Commercial Airplanes production ramps, while saying investor interest would probably pivot toward the company’s cash guidance. Harned also called out a set of one-time items that affected the quarter’s results, including the Jeppesen sale, integration costs tied to the Spirit acquisition, and a new charge recorded in the Boeing Defense, Space & Security division.

The company’s fourth-quarter results were described elsewhere as particularly robust. Boeing reported fourth-quarter 2025 earnings per share of $9.92, well above an anticipated loss of $0.45, and revenue of $23.9 billion compared with a forecast of $22.4 billion. Despite these outsized financial results, Boeing shares moved lower in pre-market trading following the release.

Additional details noted in coverage of the quarter include a 57% increase in fourth-quarter sales to $24 billion, framed as a recovery from a strike-affected fourth quarter in 2024, and an approximate $400 million reading for free cash flow in the period. Analysts from several firms adjusted their targets in response to the report: UBS raised its price target to $285, citing improved free cash flow and a renewed emphasis on quality and stability; RBC Capital lifted its target to $275; TD Cowen moved its target to $270 while labeling the results mixed because of a $565 million charge tied to the KC-46 program; and Vertical Research Partners increased its target to $281, pointing to operational stabilization and resolution of key portfolio items.

The mix of stronger-than-expected operating results, a modestly positive free cash flow outcome for the quarter, ongoing negative levered free cash flow over twelve months, and several listed one-time adjustments leaves the market parsing both near-term improvement and longer-term cash dynamics. Bernstein’s reiteration of an Outperform rating and a $298.00 target reflects conviction in upside potential, while InvestingPro’s Fair Value output and the pre-market stock move highlight investor caution.


What to watch next

  • Company commentary and guidance on free cash flow during the earnings call.
  • Progress updates on BCA production ramp activity and integration of one-time items such as Jeppesen and Spirit.
  • Market reaction to the combination of large quarterly earnings beats and persistent twelve-month levered free cash flow negativity.

Risks

  • Ongoing negative levered free cash flow over the last twelve months (-$6.35 billion) could weigh on Boeing’s longer-term cash position and investor sentiment - impacting capital markets and aerospace supply chains.
  • One-time items such as the Jeppesen sale, Spirit integration costs, and a new BDS charge complicate the earnings picture and may obscure underlying operational trends - relevant to aerospace and defense sectors.
  • Despite strong quarterly results, the stock moved lower in pre-market trading and InvestingPro’s Fair Value model flags potential overvaluation, indicating market sensitivity in equity and financial sectors.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026